[go: up one dir, main page]

MX2007010375A - Preparacion de quinoxalina sustituida de elevada pureza. - Google Patents

Preparacion de quinoxalina sustituida de elevada pureza.

Info

Publication number
MX2007010375A
MX2007010375A MX2007010375A MX2007010375A MX2007010375A MX 2007010375 A MX2007010375 A MX 2007010375A MX 2007010375 A MX2007010375 A MX 2007010375A MX 2007010375 A MX2007010375 A MX 2007010375A MX 2007010375 A MX2007010375 A MX 2007010375A
Authority
MX
Mexico
Prior art keywords
preparation
high purity
substituted quinoxaline
purity substituted
quinoxaline
Prior art date
Application number
MX2007010375A
Other languages
English (en)
Inventor
Timothy James Norman Watson
Frank Robert Busch
Joel Michael Hawkins
Lasson Georgios Mustakis
Terry Gene Sinay Jr
Gregory John Withbroe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MX2007010375A publication Critical patent/MX2007010375A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion comprende un procedimiento mejorado para la preparacion de quinoxalinas sustituidas por ciclacion de la correspondiente dianilina; mas particularmente, la presente invencion se refiere a un procedimiento mejorado para la preparacion de un compuesto azapolliciclico condensado con arilo que tiene la formula I y sus sales farmaceuticamente aceptables. (ver formula I).
MX2007010375A 2005-02-24 2006-02-21 Preparacion de quinoxalina sustituida de elevada pureza. MX2007010375A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65629605P 2005-02-24 2005-02-24
PCT/IB2006/000351 WO2006090236A1 (en) 2005-02-24 2006-02-21 Preparation of high purity substituted quinoxaline

Publications (1)

Publication Number Publication Date
MX2007010375A true MX2007010375A (es) 2007-09-25

Family

ID=36405938

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007010375A MX2007010375A (es) 2005-02-24 2006-02-21 Preparacion de quinoxalina sustituida de elevada pureza.

Country Status (15)

Country Link
US (1) US20080275051A1 (es)
EP (1) EP1866308B1 (es)
JP (1) JP2008531540A (es)
KR (1) KR20070098942A (es)
CN (1) CN101128462A (es)
AT (1) ATE411994T1 (es)
AU (1) AU2006217616A1 (es)
BR (1) BRPI0607838A2 (es)
CA (1) CA2598533A1 (es)
DE (1) DE602006003320D1 (es)
ES (1) ES2313625T3 (es)
IL (1) IL185013A0 (es)
MX (1) MX2007010375A (es)
RU (1) RU2007131535A (es)
WO (1) WO2006090236A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2009116260A (ru) 2006-11-09 2010-11-10 Пфайзер Продактс Инк. (Us) Полиморфные модификации никотиновых промежуточных продуктов
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
EP2268639A2 (en) 2008-05-22 2011-01-05 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
RU2012102052A (ru) 2009-06-22 2013-11-20 Тева Фармасьютикал Индастриз Лтд. Твердые формы солей варениклина и способы их получения
US20120277433A1 (en) * 2009-12-29 2012-11-01 Mahendranath Rao Narasimha Rao Process for the preparation of substituted quinoxalines
WO2011110954A1 (en) * 2010-03-09 2011-09-15 Actavis Group Ptc Ehf Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
US20120004239A1 (en) * 2010-06-11 2012-01-05 Medichem, S.A. Process for Preparing Quinoxaline Derivatives
CN113956255A (zh) * 2020-07-20 2022-01-21 威智医药有限公司 一种伐尼克兰中间体、伐尼克兰及其盐的制备方法
WO2022035434A1 (en) 2020-08-14 2022-02-17 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022222019A1 (en) * 2021-04-20 2022-10-27 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Total synthesis of varenicline
CN115894488A (zh) * 2021-08-20 2023-04-04 威智医药有限公司 低亚硝胺杂质含量的酒石酸伐尼克兰原料药及其制备方法
CN114349701B (zh) * 2022-01-07 2024-04-05 江苏豪森药业集团有限公司 一种酒石酸伐尼克兰中间体的制备方法
EP4241775A1 (en) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Tablet comprising varenicline and process of preparation thereof
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9814592B1 (pt) * 1997-12-31 2010-06-01 composto azapolicìclico condensado com arila, composição farmacêutica contendo o mesmo e seu uso na fabricação de um medicamento.
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
HRP20030910B1 (hr) * 2001-05-14 2011-11-30 Pfizer Products Inc. Tartaratne soli 5,8,14-triazatetraciklo {10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>}-heksadeka-2(11), 3,5,7,9-pentaena i pripadajućih farmaceutskih spojeva
DK1638971T3 (da) * 2003-06-04 2008-10-27 Pfizer Prod Inc Fremstilling af substitueret Quinoxaliner fra dianilinen med 2,3-dihydroxy-1,4-dioxan

Also Published As

Publication number Publication date
CN101128462A (zh) 2008-02-20
CA2598533A1 (en) 2006-08-31
DE602006003320D1 (de) 2008-12-04
AU2006217616A1 (en) 2006-08-31
EP1866308A1 (en) 2007-12-19
ATE411994T1 (de) 2008-11-15
IL185013A0 (en) 2007-12-03
RU2007131535A (ru) 2009-03-27
ES2313625T3 (es) 2009-03-01
US20080275051A1 (en) 2008-11-06
BRPI0607838A2 (pt) 2009-06-13
WO2006090236A1 (en) 2006-08-31
KR20070098942A (ko) 2007-10-05
JP2008531540A (ja) 2008-08-14
EP1866308B1 (en) 2008-10-22

Similar Documents

Publication Publication Date Title
IL185013A0 (en) Preparation of high purity substituted quinoxaline
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
MX339476B (es) Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
TW200508201A (en) Novel process for the preparation of roflumilast
TW200510301A (en) Novel compounds
TW200510303A (en) Novel compounds
MX2009009773A (es) Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
MX342683B (es) Analogos de ciclopamina.
TW200833651A (en) Processes suitable for producing macromolecular antioxidant compositions
NO20076371L (no) Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner
UA91535C2 (en) IMIDAZO(1, 2-a)PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
PL1682530T3 (pl) Podstawione pirolo-indole jako inhibitory PAI-1
PL1633697T3 (pl) Sposób wytwarzania podstawionych związków 3-arylo-butylo-aminowych
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
MX2010005809A (es) Proceso de dehidrohalogenacion para la preparacion de intermediarios utiles en el suministro de compuestos 6,6-dimetil-3-azabiciclo-[3,1,0]-hexano.
IL176142A0 (en) Processes for preparing montelukast sodium
MX2010004546A (es) Nuevos intermedios de pregabalina y procedimiento para prepararlos y para preparar pregabalina.
TW200700414A (en) Novel pharmaceutical compounds
TN2009000536A1 (en) Novel herbicides
NO20081617L (no) Metoder for fremstilling av Glutaminsyrederivater
TW200728258A (en) Novel compounds
TW200510323A (en) Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
WO2006075139A3 (en) Novel process for the preparation of substituted indoles
TW200738713A (en) Diazepinoquinolines, synthesis thereof, and intermediates thereto

Legal Events

Date Code Title Description
FA Abandonment or withdrawal